BIOGRAPHY
<< Back
Bruce Johnson
Bruce joined GlycoMimetics in 2022 and has worldwide commercial responsibility for the GlycoMimetics pipeline.
Bruce has more than 25 years’ experience in the biopharma industry with a solid track record of leading multi-billion commercial franchises with responsibility for achieving commercialization, establishing novel capabilities, and improving profitability. He has successfully led product launches across a variety of disease areas, including breast, lung, kidney, melanoma and neuroendocrine tumors, as well as a wide range of hematologic malignancies and rare diseases. His direct launch experience includes Jakavi, Gleevec/Glivec, Rydapt, and Tasigna in hematology as well as Afinitor, Sandostatin/Sandostatin LAR, and Zometa in solid tumors.
Previously, Bruce was Executive Vice President and Chief Commercial Officer of the digital health company Cancer Expert Now, Inc. He helped lead the organization to national recognition by Inc. Magazine as one of the Top 500 fastest-growing small companies in America. He worked for 25 years at Novartis, where he held several executive global and regional roles, including Vice President and Global Franchise Head, Malignant Hematology and Vice President and Global Disease Leader, Leukemia Franchise. He has also worked for AbbVie, Sandoz and Memorial Sloan-Kettering Cancer Center.
Bruce received a bachelor’s degree in Microbiology from Miami University (Oxford, Ohio). His education includes graduate work at Columbia University in Biochemistry and Molecular Biology and at Rutgers University School of Management in Marketing and Finance.